

Idiopathic Pulmonary Fibrosis Clinical Trial

PROTOCOL NUMBER: GS-US-231-0101	
ARTEMIS-IPF	
Official Title	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of <u>A</u> mbrisen <u>t</u> an in Subjects with <u>E</u> arly Idiopathic Pul <u>m</u> onary <u>F</u> ibrosis (IPF)
Purpose	The purpose of this study is to test the safety and effectiveness of an experimental drug called ambrisentan for the possible treatment of IPF.
Investigational Drug	Ambrisentan
Select Inclusion Criteria	<ul style="list-style-type: none"> • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based on the protocol-specified criteria in accordance with ATS-ERS guidelines for diagnosing IPF • Forced vital capacity (FVC) > 50 to ≤ 95% of predicted with a ratio of FEV1 (L) / FVC (L) ≥ 0.7. Pulmonary function tests must be completed no more than 90 days before enrollment • Ability to perform and complete 6MWT at screening • Willingness to undergo RHC at baseline and at Visit 7 or end of study(EOS)
Status	Open to enrollment
Contact Information	Research Coordinator: Amy Viccora, RN, Ph: 703-776-3697, email: amy.viccora@inova.org Principal Investigator: Steven Nathan, MD